SAN DIEGO – Jan. 29, 2018 – Millennium Health, LLC, a leading health solutions company, is proud to announce that it is now a credentialed laboratory under Medi-Cal, California’s Medicaid program. Physicians can now order the Company’s clinical services for Medi-Cal’s 2.5 million fee-for-service members. Millennium Health’s offerings approved under Medi-Cal include Millennium UDTSM and Millennium OFTSM. Also included is DxWound, a DNA test under Millennium Health’s genetics brand, CogenDx.
Millennium Health’s medication monitoring services include Millennium UDTSM (urine drug testing) and Millennium OFTSM (oral fluid testing), which enable health care professionals to monitor the use or misuse of prescription medications, non-prescribed medications and illicit substances. Information from these tests help support improved clinical decision making.
DxWound uses DNA-based technology to provide accurate and sensitive detection of an array of microbes, including aerobic and anaerobic bacteria, fungi, and antibiotic resistance genes. The test equips clinicians with information about the wound microbiome that may help them effectively and rapidly navigate important treatment decisions for their patients.
“We’re proud to partner with Medi-Cal so that we can help clinicians make informed treatment decisions for their patients,” said Nikhil Nayak, chief marketing officer, Millennium Health.
About Millennium Health
Millennium Health is transforming the way medications are prescribed by providing accurate, timely and actionable information that helps clinicians optimize treatment decisions for their patients. We offer a suite of services that includes Millennium PGTSM, Millennium UDTSM and Millennium OFTSM. Our genetics brand, CogenDx, offers DxWound and DxSurgical. Millennium Health’s comprehensive health solutions provide Personalized Medication Intelligence. More information can be found at www.millenniumhealth.com.
CogenDx, the genetics brand of Millennium Health, LLC, enables clinicians to personalize treatment decisions for patients using state-of-the-art molecular diagnostic technology. Our portfolio includes DxWound, a proprietary DNA-based tool that helps clinicians rapidly determine course of therapy for patients with suspected wound infections. We also offer DxSurgical, a genetic test that helps predict response to commonly prescribed medications and determine genetic risks underlying certain potential surgical complications. More information can be found at www.cogendx.com.